Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Locally Advanced Bladder Cancer 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Temozolomide 1Radiotherapy 1Pharmaceutical Preparations 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1HMPL-013 1Fluoxetine 1Fluorouracil 1Cisplatin 1Cholecalciferol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Adenocarcinoma × Pharmaceutical Preparations × Clear all
NCT05635149 2022-12-02

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Unknown
100 enrolled
Gastrointestinal

Colorectal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡